
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion is positioned to disrupt the metabolic disease market with its promising drug pipeline and has strong potential for growth and success.
Bears say
Biomea Fusion is a clinical stage diabetes and obesity medicines company with promising drug candidates in development, however, there is limited data to fully support the efficacy of their lead candidate, icovamenib. Additionally, with over 60 approved therapies for diabetes and none addressing the central driver of disease progression, the market potential for Biomea's drugs may be overstated. Furthermore, the company's early stage drug, BMF-650, has yet to show significant weight loss results and its tolerability is still a concern. Overall, the limited data and potential competition in the market make Biomea Fusion's stock a risky investment at this time.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares